CMV disease among 119 transplant recipients with CMV antigenemia, according to antigenemia trend and antiviral strategy.

CMV disease developed in 16 of 115 evaluable patients with CMV antigenemia. All cases of early CMV disease took place among patients with rising antigenemia levels who were not re-induced with antivirals (ie, continued on maintenance doses); 3 of 4 of these patients died with CMV disease. Antigenemia course or antiviral strategy did not seem to predict the development of late CMV disease. † indicates that antigenemia trend could not be assessed as a risk factor for disease (see text); *, increases in pp65 antigenemia from “baseline” value (for definition, see text).